Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00009646
Other study ID # NICHD-NRN-0011
Secondary ID U10HD034216U10HD
Status Completed
Phase Phase 3
First received February 1, 2001
Last updated June 3, 2015
Start date November 1993
Est. completion date March 2001

Study information

Verified date June 2015
Source NICHD Neonatal Research Network
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review BoardUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This trial was to determine whether giving low-dose indomethacin to infants weight 500 to 999 grams (approximately 1 to 2 pounds) at birth improves their survival without cerebral palsy or developmental problems at 18 to 22 months of age.


Description:

Prophylactic indomethacin reduces patent ductus arteriosus (PDA) and intraventricular hemorrhage in very low birth weight infants. However, the effects of early indomethacin on long-term neurodevelopment remain uncertain. There is also insufficient evidence to rule out serious adverse effects, such as increases in the risk of necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP). The aim of this trial was to determine if prophylactic administration of indomethacin improves survival without neurosensory impairments in extremely-low-birth-weight infants. Infants (n=1202) with birthweights 500 to 999 grams were randomized between 2 and 6 hours after birth to receive either intravenous indomethacin (0.1 mg/kg) or equal volumes of normal saline placebo, daily for 3 days. The primary outcomes at a corrected age of 18 months was a composite of death, cerebral palsy, cognitive delay, deafness, or blindness. Secondary long-term outcomes were hydrocephalus necessitating the placement of a shunt, seizure disorder, and microcephaly. Secondary short-term outcomes were patent ductus arteriosus, pulmonary hemorrhage, chronic lung disease, cranial ultrasonographic abnormalities, nectrotizing enterocolitis and retinopathy. Infants were evaluated in follow-up at 18-22 months corrected age.


Recruitment information / eligibility

Status Completed
Enrollment 1202
Est. completion date March 2001
Est. primary completion date March 1999
Accepts healthy volunteers No
Gender Both
Age group N/A to 6 Hours
Eligibility Inclusion Criteria:

- Birth weight 500 to 999 grams;

- Postnatal age greater than 2 hours;

Exclusion Criteria:

- Unable to administer study drug within 6 hours of birth;

- Structural heart disease and/or renal disease;

- Dysmorphic features or congenital abnormalities;

- Tocolytic therapy with indomethacin or other prostaglandin inhibitor within 72 hours prior to delivery;

- Overt clinical bleeding from more than one site;

- Platelet count less than 50 x 109/L;

- Hydrops;

- Not considered viable

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Intervention

Drug:
indomethacin
Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
Indomethacin
0.1 mg per kilogram of body weight
Placebo
0.1 mg per kilogram of body weight

Locations

Country Name City State
United States University of New Mexico Albuquerque New Mexico
United States Emory University Atlanta Georgia
United States University of Alabama at Birmingham Birmingham Alabama
United States Case Western Reserve University, Rainbow Babies and Children's Hospital Cleveland Ohio
United States University of Texas Southwestern Medical Center at Dallas Dallas Texas
United States Wayne State University Detroit Michigan
United States University of Miami Miami Florida
United States Stanford University Palo Alto California
United States Brown University, Women & Infants Hospital of Rhode Island Providence Rhode Island

Sponsors (3)

Lead Sponsor Collaborator
NICHD Neonatal Research Network Medical Research Council of Canada, National Center for Research Resources (NCRR)

Country where clinical trial is conducted

United States, 

References & Publications (8)

Alfaleh K, Smyth JA, Roberts RS, Solimano A, Asztalos EV, Schmidt B; Trial of Indomethacin Prophylaxis in Preterms Investigators. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the tria — View Citation

Ambalavanan N, Baibergenova A, Carlo WA, Saigal S, Schmidt B, Thorpe KE; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Early prediction of poor outcome in extremely low birth weight infants by classification tree analysis. J Pediatr. — View Citation

Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS; Trial of Indomethacin Prophylaxis in Preterms Investigators. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role o — View Citation

Clyman RI, Saha S, Jobe A, Oh W. Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. J Pediatr. 2007 Jan;150(1):46-50.e2. — View Citation

Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from th — View Citation

Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth- — View Citation

Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M, Wright LL; Trial of Indomethacin Prophylaxis in Preterms Investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J M — View Citation

Schmidt B, Roberts RS, Fanaroff A, Davis P, Kirpalani HM, Nwaesei C, Vincer M; TIPP Investigators. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Death or Neurodevelopment Impairment 18-22 Months Corrected Age Yes
Secondary Patent ductus arteriosus 120 Days of Life Yes
Secondary Bronchopulmonary Dysplasia (BPD) Chronic Lung Disease (CLD) 120 Days of Life Yes
Secondary Necrotizing enterocolitis (NEC) 120 Days of Life Yes
Secondary Intracranial abnormalities 120 Days of Life Yes
Secondary Retinopathy of Prematurity (ROP) 18-22 Months Corrected Age Yes
Secondary Pulmonary hemorrhage 120 Days of Life Yes
See also
  Status Clinical Trial Phase
Completed NCT03146351 - The Effects of Family Centered Intervention Program on Preterm Infants N/A
Completed NCT02064712 - Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates N/A
Completed NCT00365703 - Nasogastric Tube vs. Orogastric Feeding Tube in Preterm Infants: Which is Best? N/A
Terminated NCT00179933 - The Impact of Implementing NIDCAP on Preterm Infants in the NICU N/A
Completed NCT00114543 - Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Phase 3
Terminated NCT05030012 - Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants N/A
Completed NCT00552383 - The Edmonton Randomised Controlled Trial of NIDCAP - Based Developmental Care N/A
Completed NCT00011362 - Dexamethasone Therapy in VLBW Infants at Risk of CLD Phase 3
Completed NCT06308471 - Effect of Baby Massage on Oral Motor Skills of Premature Babies N/A
Completed NCT01863043 - Aspiration of Residual Gastric Contents N/A
Completed NCT05462509 - Feasibility of Use of the PATH bCPAP and Oxygen Blenders Device With Neonates in Uganda N/A
Not yet recruiting NCT06109350 - The Effect of Physical Therapy Intervention on Motor Performance in Bhutanese Preterm Infants N/A
Terminated NCT02599545 - Testosterone and Cortisol Levels in Infants
Completed NCT03551600 - Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
Completed NCT02611284 - Less Invasive Beractant Administration in Preterm Infants N/A
Completed NCT01193270 - Vitamin E for Extremely Preterm Infants Phase 1
Completed NCT00455169 - Influenza Vaccine in Premature Infants Phase 4
Withdrawn NCT00536445 - Use of NAVA in Intubated Preterm Phase 1/Phase 2
Completed NCT00579553 - Comparing IM vs. Vaginal Progesterone for Pre-term Birth N/A
Completed NCT01203423 - Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study